Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
GlycoMimetics Announces Publication of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial of GMI-1359
April 22, 2019 Off

GlycoMimetics Announces Publication of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial of GMI-1359

By BusinessWire

Preclinical studies indicatethat targeting both E-selectin and CXCR4 with a single compound couldimprove efficacy in the treatment of cancers that involve the bonemarrow such as AML and multiple myeloma or in solid tumors thatmetastasize to the bone, such as prostate cancer and breast cancer.

Novus Therapeutics Announces Results of Two Single-Dose OP0201 Phase 1 Clinical Trials
April 22, 2019 Off

Novus Therapeutics Announces Results of Two Single-Dose OP0201 Phase 1 Clinical Trials

By BusinessWire

Novus said the results from single-dose phase 1 studies met theprimary objectives and demonstrated a favorable safety and tolerabilityprofile

KalVista Pharmaceuticals Appoints Daniel B. Soland to Board of Directors
April 22, 2019 Off

KalVista Pharmaceuticals Appoints Daniel B. Soland to Board of Directors

By BusinessWire

Daniel Soland has been appointed to Kalvista Board of Directors .

Aura Biosciences to Present Two Year Phase 1b/2 Clinical Data for AU-011 at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting
April 22, 2019 Off

Aura Biosciences to Present Two Year Phase 1b/2 Clinical Data for AU-011 at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting

By BusinessWire

Aura Biosciences’ lead productcandidate for the primary treatment of primary choroidal melanoma, willbe highlighted in a poster presentation at the Association for Researchin Vision and Ophthalmology (ARVO) 2019 Annual Meeting

CMS Establishes Unique J-Code for BELRAPZO™ (Bendamustine 500mL Hydrochloride Injection)
April 22, 2019 Off

CMS Establishes Unique J-Code for BELRAPZO™ (Bendamustine 500mL Hydrochloride Injection)

By BusinessWire

BELRAPZO is indicated for the treatment of patients with indolent B-cellnon-Hodgkin lymphoma (NHL) that has progressed during or within sixmonths of treatment with rituximab or a rituximab-containing regimen.

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)
April 22, 2019 Off

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)

By BusinessWire

many patients with advancedrenal cell carcinoma need additional treatment options that can helpimprove survival outcomes

April 22, 2019 Off

AscellaHealth Supports DEA’s National Prescription Drug Take Back Day, Points to SafeUseNow℠ Solution to Combat Spread of Prescription Drug Abuse

By BusinessWire

BERWYN, Pa.–(BUSINESS WIRE)–In recognition of the Drug Enforcement Administration’s (DEA) National Prescription Drug Take Back Day, April 27, 2019, AscellaHealth…

Susmed: Demonstration of Clinical Data Managing System Using Blockchain Technology
April 22, 2019 Off

Susmed: Demonstration of Clinical Data Managing System Using Blockchain Technology

By BusinessWire

In this pilot project, the Susmed system uses blockchain technology, which isexpected to be more cost-effective than conventional methods inmonitoring of clinical researches and ensuring data accuracy duringmonitoring.

FSD Pharma Receives Cannabis Sales License from Health Canada
April 22, 2019 Off

FSD Pharma Receives Cannabis Sales License from Health Canada

By BusinessWire

The license allows the current FSD facility to supply and sell cannabisproducts. The company expects receiving the amended sales licensethat will include the sale of dried and fresh cannabis flower in thenear future.

Global Anticoagulants Reversal Drugs Market Covering Key Players & Their Competitive Strategies, 2019: Analysis & Outlook Through 2018-2026 – ResearchAndMarkets.com
April 19, 2019 Off

Global Anticoagulants Reversal Drugs Market Covering Key Players & Their Competitive Strategies, 2019: Analysis & Outlook Through 2018-2026 – ResearchAndMarkets.com

By BusinessWire

The global anticoagulants reversal drugs market expected to expand at aCAGR of 15.3% from 2018 to 2026, owing to the approval of blockbusterdrugs in recent years and strong pipeline driving the market.

Posts pagination

Previous 1 … 3,261 3,262 3,263 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine